Integrating biosimilars into health systems pharmacies
Biosimilars are reshaping the treatment landscape for biologic-based therapies. In addition to producing clinically-equivalent outcomes to their reference products, studies show biosimilars will contribute to lowering the overall cost of healthcare.
To help Pharmacy & Therapeutics (P&T) committees determine whether biosimilars are appropriate for their health system’s formulary, pharmacy leaders will need to help address three current barriers to adoption: physician support, operational concerns and potential economic considerations.
To read the full article, as originally published in Becker's Hospital Review, click here.
Supply chain tip of the day: Understand biosimilar nuances before integrating them into the system
Biosimilars are creating new cost-saving opportunities for health system pharmacies, but before pharmacy leaders integrate biosimilars into their health system, they must understand their nuances.
Biosimilars: Strategies for Utilization in the Health System Setting
As biosimilars enter the market, they have the potential to reshape the treatment landscape. In this informative webinar, leading experts will share how these options create opportunities for health system pharmacy leaders.